Qunaj, L., Lentzsch, S., & Neugut, A. I. (2024). The Undetermined Significance of Screening for Monoclonal Gammopathy of Undetermined Significance. Cancer Epidemiology, Biomarkers & Prevention, 33(12), 1547–1549. https://doi.org/10.1158/1055-9965.epi-24-1405

Cicero, K. I., Dlamini, X., Mavengere, Y., Justman, J., Nuwagaba-Biribonwoha, H., Dlamini, S., Dlamini, M., Ngwenyama, S., Ngcamphalala, C., Low, A., Philip, N. M., El-Sadr, W. M., Sahabo, R., Abreha, T., Temesgen, S., Mahlalela, N., Chiuzan, C., Chen, Y., Pan, S. S., … Neugut, A. I. (2024). Prevalence of monoclonal gammopathy of undetermined significance in Eswatini: a population-based study in Africa. JNCI Cancer Spectrum, 8(4). https://doi.org/10.1093/jncics/pkae056

Gordon, E. R., Chen, C., Trager, M. H., Adeuyan, O., Lapolla, B. A., Fahmy, L. M., Schreidah, C. M., Wetter, D. A., & Geskin, L. J. (2024). Gammopathic dermopathy: characterization of cutaneous MGUS. Leukemia & Lymphoma, 65(7), 989–996. https://doi.org/10.1080/10428194.2024.2336046

Gordon, E. R., Chen, C., Adeuyan, O., Lapolla, B. A., Trager, M. H., Fahmy, L. M., Schreidah, C. M., Wetter, D. A., & Geskin, L. J. (2024). Retrospective analysis of multiple myeloma drug use in cutaneous toxicity of monoclonal gammopathy of undetermined significance. Journal of the American Academy of Dermatology, 91(1), 129–130. https://doi.org/10.1016/j.jaad.2024.02.050

Mohyuddin, G. R., Chakraborty, R., & Cliff, E. R. S. (2023). The promise and harms of screening for plasma cell dyscrasias. British Journal of Haematology, 200(6), 704–707. Portico. https://doi.org/10.1111/bjh.18634

Cicero, K. I., Joffe, M., Patel, M., Chiuzan, C., Pentz, A., Ruff, P., Lentzsch, S., Leng, S., Jacobson, J. S., Rebbeck, T. R., & Neugut, A. I. (2022). Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men. Cancer Epidemiology, Biomarkers & Prevention, 31(12), 2192–2198. https://doi.org/10.1158/1055-9965.epi-22-0525